Pharma

Novartis, Shionogi, ArriVent—Fierce Pharma Asia

Novartis bought an mRNA-coded autoimmune T-cell engager. Shionogi will pay $2 billion to acquire IntraBio. ArriVent's EGFR inhibitor failed in phase 3.

Angus Liu Oct 9, 2026 8:30am

A pile of ham sandwhiches on top of each other on a plate

Free lunches for clinicians bloat prescription bills: review

Oct 9, 2026 5:33am

For biopharma manufacturing at speed and scale, the future is flexible

Brought to you by Resilience

sketching charcoal filling in filling out fill in fill out sketch

BMS is augmenting Zenbexus' efficacy profile in multiple myeloma

Oct 8, 2026 2:25pm

Clinical trials reach a new automation inflection point

Brought to you by IQVIA

Pfizer's Tukysa approved as first-line maintenance therapy

Oct 8, 2026 11:25am